DAFNA Capital Management »

Editas Medicine shares owned by DAFNA Capital Management

Quarter-by-quarter ownership of Editas Medicine (EDIT) shares owned by DAFNA Capital Management from 13F filings

Historical chart of DAFNA Capital Management investment in Editas Medicine

Tip: Access up to 7 years of quarterly data

All positions including Editas Medicine held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Editas Medicine by DAFNA Capital Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $552k 171k 3.24

More positions owned by DAFNA Capital Management

Revolution Medicines (RVMD)
Spdr S&p Biotech Etf Etf (XBI)
Compass Pathways Sponsored Ads (CMPS)
Stereotaxis Com New (STXS)
Nektar Therapeutics Com New (NKTR)
Denali Therapeutics (DNLI)
Ideaya Biosciences (IDYA)
AtriCure (ATRC)
Xenon Pharmaceuticals (XENE)
Cytokinetics Com New (CYTK)
Arcus Biosciences Incorporated (RCUS)
Ascendis Pharma A/s Ord Shs (ASND)
Neurocrine Biosciences (NBIX)
Axogen (AXGN)
Insulet Corporation (PODD)

View all positions for DAFNA Capital Management

Top funds holding Editas Medicine

TCG Crossover Management
BlackRock
ADAR1 Capital Management
RA Capital Management
Commodore Capital
Vanguard Capital Management
Paradigm Biocapital Advisors
Opaleye Management
Vanguard Portfolio Management
Woodline Partners
Vivo Capital
Goldman Sachs Group
Geode Capital Management
Renaissance Technologies
Logos Global Management

View all funds holding Editas Medicine